{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T14:03:33Z","timestamp":1788185013584,"version":"build-2803163510"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,22]]},"DOI":"10.7759\/cureus.92896","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T08:21:16Z","timestamp":1758529276000},"source":"Crossref","is-referenced-by-count":3,"title":["Gastrointestinal Dysautonomia: A Rare Immune-Related Adverse Event That Requires Early Recognition and High-Dose Immunosuppression"],"prefix":"10.7759","author":[{"given":"Benjamin","family":"Norton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Sennfalt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross","family":"Nortley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Nathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Iodice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Zarate-Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisling","family":"Carr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand Y","year":"2022","unstructured":"Shiravand Y, Khodadadi F, Kashani SM, et al.. Immune checkpoint inhibitors in cancer therapy. Curr Oncol. 2022, 29:3044-60. 10.3390\/curroncol29050247","journal-title":"Curr Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2022.09.004","article-title":"Immune checkpoint inhibitor therapy in\u00a0oncology: current uses and future directions: JACC: cardiooncology state-of-the-art review","volume":"4","author":"Tan S","year":"2022","unstructured":"Tan S, Day D, Nicholls SJ, Segelov E. Immune checkpoint inhibitor therapy in\u00a0oncology: current uses and future directions: JACC: cardiooncology state-of-the-art review. JACC CardioOncol. 2022, 4:579-97. 10.1016\/j.jaccao.2022.09.004","journal-title":"JACC CardioOncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow MA","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018, 378:158-68. 10.1056\/NEJMra1703481","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.2535","article-title":"Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs","volume":"2","author":"Haslam A","year":"2019","unstructured":"Haslam A, Prasad V. Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Netw Open. 2019, 2:e192535. 10.1001\/jamanetworkopen.2019.2535","journal-title":"JAMA Netw Open"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.e14613","article-title":"Updated estimates of eligibility and response: immune checkpoint inhibitors","volume":"42","author":"Prasad V","year":"2024","unstructured":"Prasad V, Haslam A, Olivier T. Updated estimates of eligibility and response: immune checkpoint inhibitors. J Clin Oncol. 2024, 42:e14613. 10.1200\/JCO.2024.42.16_suppl.e14613","journal-title":"J Clin Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen J","year":"2022","unstructured":"Haanen J, Obeid M, Spain L, et al.. Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022, 33:1217-38. 10.1016\/j.annonc.2022.10.001","journal-title":"Ann Oncol"},{"key":"ref7","article-title":"Diagnosis and management of immune checkpoint inhibitor colitis","volume":"17","author":"Hashash JG","year":"2021","unstructured":"Hashash JG, Francis FF, Farraye FA. Diagnosis and management of immune checkpoint inhibitor colitis. Gastroenterol Hepatol (N Y). 2021, 17:358-66.","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0396-9","article-title":"Fatal enteric plexus neuropathy after one dose of ipilimumab plus nivolumab: a case report","volume":"6","author":"Appelbaum J","year":"2018","unstructured":"Appelbaum J, Wells D, Hiatt JB, et al.. Fatal enteric plexus neuropathy after one dose of ipilimumab plus nivolumab: a case report. J Immunother Cancer. 2018, 6:82. 10.1186\/s40425-018-0396-9","journal-title":"J Immunother Cancer"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-11667-5","article-title":"Dysautonomia associated with immune checkpoint inhibitors","volume":"270","author":"Tezuka T","year":"2023","unstructured":"Tezuka T, Okuzumi S, Nakashima C, et al.. Dysautonomia associated with immune checkpoint inhibitors. J Neurol. 2023, 270:3413-23. 10.1007\/s00415-023-11667-5","journal-title":"J Neurol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.12.001","article-title":"Neurological adverse events associated with immune checkpoint inhibitors: review of the literature","volume":"73","author":"Cuzzubbo S","year":"2017","unstructured":"Cuzzubbo S, Javeri F, Tissier M, et al.. Neurological adverse events associated with immune checkpoint inhibitors: review of the literature. Eur J Cancer. 2017, 73:1-8. 10.1016\/j.ejca.2016.12.001","journal-title":"Eur J Cancer"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0487","article-title":"Neurologic serious adverse events associated with nivolumab plus ipilimumab or nivolumab alone in advanced melanoma, including a case series of encephalitis","volume":"22","author":"Larkin J","year":"2017","unstructured":"Larkin J, Chmielowski B, Lao CD, et al.. Neurologic serious adverse events associated with nivolumab plus ipilimumab or nivolumab alone in advanced melanoma, including a case series of encephalitis. Oncologist. 2017, 22:709-18. 10.1634\/theoncologist.2016-0487","journal-title":"Oncologist"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.gtc.2008.02.005","article-title":"Enteric autoantibodies and gut motility disorders","volume":"37","author":"Kashyap P","year":"2008","unstructured":"Kashyap P, Farrugia G. Enteric autoantibodies and gut motility disorders. Gastroenterol Clin North Am. 2008, 37:397-410. 10.1016\/j.gtc.2008.02.005","journal-title":"Gastroenterol Clin North Am"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1177\/2040622320970354","article-title":"Gastrointestinal side effects of cancer treatments","volume":"11","author":"O'Reilly M","year":"2020","unstructured":"O'Reilly M, Mellotte G, Ryan B, O'Connor A. Gastrointestinal side effects of cancer treatments. Ther Adv Chronic Dis. 2020, 11:2040622320970354. 10.1177\/2040622320970354","journal-title":"Ther Adv Chronic Dis"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin J","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, et al.. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015, 373:23-34. 10.1056\/NEJMoa1504030","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert C","year":"2015","unstructured":"Robert C, Schachter J, Long GV, et al.. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015, 372:2521-32. 10.1056\/NEJMoa1503093","journal-title":"N Engl J Med"},{"key":"ref16","article-title":"Ipilimumab-induced Guillain-Barr\u00e9 syndrome presenting as dysautonomia: an unusual presentation of a rare complication of immunotherapy","volume":"40","author":"Kelly Wu W","year":"2017","unstructured":"Kelly Wu W, Broman KK, Brownie ER, Kauffmann RM. Ipilimumab-induced Guillain-Barr\u00e9 syndrome presenting as dysautonomia: an unusual presentation of a rare complication of immunotherapy. J Immunother. 2017, 40:196-9.","journal-title":"J Immunother"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1136\/pn-2024-004327","article-title":"Neurological complications of immune checkpoint inhibitors: a practical guide","volume":"25","author":"Carr AS","year":"2025","unstructured":"Carr AS, Vonberg FW, Koay S, Young K, Shaw H, Olsson-Brown A, Willis M. Neurological complications of immune checkpoint inhibitors: a practical guide. Pract Neurol. 2025, 25:116-26. 10.1136\/pn-2024-004327","journal-title":"Pract Neurol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/364250-gastrointestinal-dysautonomia-a-rare-immune-related-adverse-event-that-requires-early-recognition-and-high-dose-immunosuppression","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T08:21:17Z","timestamp":1758529277000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/364250-gastrointestinal-dysautonomia-a-rare-immune-related-adverse-event-that-requires-early-recognition-and-high-dose-immunosuppression"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,22]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.92896","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,22]]}}}